Genetic and Preventive Services for Hereditary Breast and Ovarian Cancer in the Czech Republic

Tekijä Foretova, Lenka, Petrakova, Katarina, Palacova, Marketa, Kalabova, Renata, Navratilova, Marie, Lukesova, Miroslava, Vasickova, Petra, Machackova, Eva, Kleibl, Zdenek, Pohlreich, Petr
Julkaistu 2006

Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based...

Tekijä Holanek, Milos, Selingerova, Iveta, Bilek, Ondrej, Kazda, Tomas, Fabian, Pavel, Foretova, Lenka, Zvarikova, Maria, Obermannova, Radka, Kolouskova, Ivana, Coufal, Oldrich, Petrakova, Katarina, Svoboda, Marek, Poprach, Alexandr
Julkaisussa Cancers (Basel) (2021)

Impact of Hormone Receptor Status on the Behaviour of HER2+ Breast Cancer

Tekijä KOLAROVA, IVETA, DUSEK, LADISLAV, RYSKA, ALES, ODRAZKA, KAREK, DOLEZEL, MARTIN, VANASEK, JAROSLAV, MELICHAR, BOHUSLAV, PETERA, JIRI, BUCHLER, TOMAS, VOSMIK, MILAN, PETRAKOVA, KATARINA, TERAROVA, PETRA, VILASOVA, ZDENA, JARKOVSKY, JIRI
Julkaisussa In Vivo (2020)

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial

Tekijä O’Shaughnessy, Joyce, Petrakova, Katarina, Sonke, Gabe S., Conte, Pierfranco, Arteaga, Carlos L., Cameron, David A., Hart, Lowell L., Villanueva, Cristian, Jakobsen, Erik, Beck, Joseph T., Lindquist, Deborah, Souami, Farida, Mondal, Shoubhik, Germa, Caroline, Hortobagyi, Gabriel N.
Julkaisussa Breast Cancer Res Treat (2017)

Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Tekijä Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Julkaistu 2013

Erratum to: Everolimus Plus Exemestane in Postmenopausal Patients with HR(+) Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis

Tekijä Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.
Julkaisussa Adv Ther (2014)

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 tri...

Tekijä Krop, Ian E, Mayer, Ingrid A, Ganju, Vinod, Dickler, Maura, Johnston, Stephen, Morales, Serafin, Yardley, Denise A, Melichar, Bohuslav, Forero-Torres, Andres, Lee, Soo Chin, de Boer, Richard, Petrakova, Katarina, Vallentin, Susanne, Perez, Edith A, Piccart, Martine, Ellis, Matthew, Winer, Eric, Gendreau, Steven, Derynck, Mika, Lackner, Mark, Levy, Gallia, Qiu, Jiaheng, He, Jing, Schmid, Peter
Julkaisussa Lancet Oncol (2016)

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

Tekijä Rugo, Hope S., Im, Seock-Ah, Cardoso, Fatima, Cortés, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D., Wright, Gail S., Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A., Freedman, Orit, Jakobsen, Erik H., Kaufman, Bella, Yerushalmi, Rinat, Fasching, Peter A., Nordstrom, Jeffrey L., Bonvini, Ezio, Koenig, Scott, Edlich, Sutton, Hong, Shengyan, Rock, Edwin P., Gradishar, William J.
Julkaisussa JAMA Oncol (2021)